What is Sensimed?
Based in Lausanne, Switzerland, Sensimed is the developer of the SENSIMED Triggerfish, a groundbreaking smart contact lens designed to provide a comprehensive 24-hour profile of eye health. By addressing the critical need for continuous intraocular pressure monitoring, the company has carved out a unique niche in the MedTech sector. Sensimed serves a specialized market of healthcare professionals and clinical organizations, offering a technological advantage that traditional, intermittent diagnostic methods cannot replicate. The firm's commitment to revolutionizing glaucoma management positions it as a key player in the digital health and diagnostic device landscape.
How much funding has Sensimed raised?
Sensimed has raised a total of $24.8M across 2 funding rounds:
Series A
$6.9M
Series C
$17.9M
Series A (2007): $6.9M with participation from Wellington Partners, BlueOcean Ventures, and VINCI CAPITAL
Series C (2012): $17.9M led by Agate Medical Investments, ELM Development, Wellington Partners, Vinci Capital/Renaissance PME, and Sandoz Fmaily Foundation
Key Investors in Sensimed
Wellington Partners
A leading European venture capital firm that invests in early- and growth-stage life science companies, including medical devices and digital health.
Agate Medical Investments
A venture capital firm specializing in providing growth capital to mature MedTech companies, with a focus on Israel-related healthcare innovations.
BlueOcean Ventures
An investment company focused on early-stage medical device and life science companies, providing strategic guidance and financial backing to startups.
What's next for Sensimed?
With the support of its institutional backers, Sensimed is well-positioned to accelerate the commercial adoption of its diagnostic platform. The current lifecycle stage, characterized by major enterprise-level funding, suggests a strategic focus on expanding clinical integration and enhancing the data analytics capabilities of the Triggerfish system. Future growth will likely center on securing broader regulatory approvals and deepening partnerships within the global ophthalmology community to establish the SENSIMED Triggerfish as the gold standard for glaucoma monitoring and patient-centric eye care.
See full Sensimed company page
